StockNews.AI
ALVO
StockNews.AI
109 days

Alvotech Announces Webcast of First Quarter 2025 Financial Results on May 8, 2025, at 8:00 am EDT (14:00 CET)

1. Alvotech will release Q1 2025 financial results on May 7. 2. Conference call for analysts scheduled for May 8 at 8 AM EDT. 3. Two biosimilars are already marketed; nine candidates are in development. 4. Alvotech aims to be a leader in the global biosimilar market. 5. Strong partnerships enhance Alvotech's market reach across multiple regions.

Earnings
+3.53%Current Return
VS
+1.48%S&P 500
$7.9405/02 08:35 AM EDTEvent Start
$8.2205/05 08:56 AM EDTLatest Updated
5m saved
Insight
Article

FAQ

Why Bullish?

The upcoming earnings report could demonstrate positive growth, reflecting management's strategic focus. Historical examples show earnings reports often lead to market uplift when expectations are met or exceeded.

How important is it?

The earnings release is significant due to its potential to influence investor sentiment and stock price.

Why Short Term?

The imminent earnings report may lead to immediate market reactions; past earnings releases show similar patterns in stock movement.

Related Companies

TEVASTDARDYCPBFPL
Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced today that it will release financial results for the first quarter ended March 31, 2025, after U.S. markets close on Wednesday, May 7, 2025. Alvotech will also conduct a conference call with analysts to present the financial results and recent business highlights on Thursday May 8, 2025, at 8:00 am EDT (12:00 noon GMT, 14:00 CET).   Live audio of the conference call will be webcast and available to members of the news media, investors, and the general public. Information on how to access the webcast or participate by conference call is posted on Alvotech’s investor website https://investors.alvotech.com. Links to access the webcast or sign in number for analysts is found at https://investors.alvotech.com/events/event-details/q1-2025-earnings. The webcast will also be archived and available for replay for 90 days after the event. About AlvotechAlvotech is a biotech company, founded by Robert Wessman, focused solely on the development and manufacture of biosimilar medicines for patients worldwide. Alvotech seeks to be a global leader in the biosimilar space by delivering high quality, cost-effective products, and services, enabled by a fully integrated approach and broad in-house capabilities. Two biosimilars, to Humira® (adalimumab) and Stelara® (ustekinumab) are already approved and marketed in multiple global markets. The current development pipeline includes nine disclosed biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Alvotech has formed a network of strategic commercial partnerships to provide global reach and leverage local expertise in markets that include the United States, Europe, Japan, China, and other Asian countries and large parts of South America, Africa and the Middle East. Alvotech’s commercial partners include Teva Pharmaceuticals, a US affiliate of Teva Pharmaceutical Industries Ltd. (US), STADA Arzneimittel AG (EU), Fuji Pharma Co., Ltd (Japan), Advanz Pharma (EEA, UK, Switzerland, Canada, Australia and New Zealand), Dr. Reddy’s (EEA, UK and US), Biogaran (FR), Cipla/Cipla Gulf/Cipla Med Pro (Australia, New Zealand, South Africa/Africa), JAMP Pharma Corporation (Canada), Yangtze River Pharmaceutical (Group) Co., Ltd. (China), DKSH (Taiwan, Hong Kong, Cambodia, Malaysia, Singapore, Indonesia, India, Bangladesh and Pakistan), YAS Holding LLC (Middle East and North Africa), Abdi Ibrahim (Turkey), Kamada Ltd. (Israel), Mega Labs, Stein, Libbs, Tuteur and Saval (Latin America) and Lotus Pharmaceuticals Co., Ltd. (Thailand, Vietnam, Philippines, and South Korea). Each commercial partnership covers a unique set of product(s) and territories. Except as specifically set forth therein, Alvotech disclaims responsibility for the content of periodic filings, disclosures and other reports made available by its partners. For more information, please visit https://www.alvotech.com. None of the information on the Alvotech website shall be deemed part of this press release. ALVOTECH INVESTOR RELATIONS AND GLOBAL COMMUNICATIONSBenedikt Stefansson, VPalvotech.ir@alvotech.com Please visit our investor portal, and our website or follow us on social media on LinkedIn, Facebook, Instagram, and YouTube.

Related News